Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art

被引:9
作者
Le Saux, Olivia [1 ]
Lounici, Yasmine [1 ]
Wajda, Pauline [1 ]
Barrin, Sarah [1 ]
Caux, Christophe [1 ]
Dubois, Bertrand [1 ]
Ray-Coquard, Isabelle [2 ]
机构
[1] Ctr Leon Berard, Ctr Rech Cancerol Lyon, CNRS 5286, Inserm 1052, F-69008 Lyon, France
[2] Ctr Leon Berard, Dept Med Oncol, 28 Rue Laennec, F-69008 Lyon, France
关键词
Immunotherapy; Cancer; Neoadjuvant; Preclinical data; BREAST-CANCER; IPILIMUMAB; THERAPY; CHEMOTHERAPY; NIVOLUMAB; BLOCKADE; OVEREXPRESSION; PEMBROLIZUMAB; CARBOPLATIN; PACLITAXEL;
D O I
10.1016/j.critrevonc.2020.103172
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Immunotherapy has been a revolution in cancer management in the metastatic setting. This has led to a prompt evaluation of such therapies in earlier stages. This article discusses the still limited amount of data finding the rationale to assess such therapy in this setting and reviews preclinical and clinical data available. Overall, neoadjuvant immunotherapy is a promising approach for the treatment of cancers and the rationale supporting its use is strong. Neoadjuvant immunotherapy resulted, in the majority of clinical trials, in improved pathologic complete response rates with a favorable toxicity profile and no delay in surgery. Various regimens were effective: inhibitory immune check-point blockers (IICPB) alone, combination of PD-1 and CTLA-4 inhibitors, combination of chemotherapy (CT) and IICPB, phased CT and IICPB (either IICPB before CT or IICPB after CT). Yet the question whether neoadjuvant immunotherapy will benefit to patients in terms of disease-free and, ultimately, overall survival remains unknown.
引用
收藏
页数:11
相关论文
共 71 条
[1]   Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma [J].
Amaria, Rodabe N. ;
Reddy, Sangeetha M. ;
Tawbi, Hussein A. ;
Davies, Michael A. ;
Ross, Merrick, I ;
Glitza, Isabella C. ;
Cormier, Janice N. ;
Lewis, Carol ;
Hwu, Wen-Jen ;
Hanna, Ehab ;
Diab, Adi ;
Wong, Michael K. ;
Royal, Richard ;
Gross, Neil ;
Weber, Randal ;
Lai, Stephen Y. ;
Ehlers, Richard ;
Blando, Jorge ;
Milton, Denai R. ;
Woodman, Scott ;
Kageyama, Robin ;
Wells, Daniel K. ;
Hwu, Patrick ;
Patel, Sapna P. ;
Lucci, Anthony ;
Hessel, Amy ;
Lee, Jeffrey E. ;
Gershenwald, Jeffrey ;
Simpson, Lauren ;
Burton, Elizabeth M. ;
Posada, Liberty ;
Haydu, Lauren ;
Wang, Linghua ;
Zhang, Shaojun ;
Lazar, Alexanderj ;
Hudgens, Courtney W. ;
Gopalakrishnan, Vancheswaran ;
Reuben, Alexandre ;
Andrews, Miles C. ;
Spencer, Christine N. ;
Prieto, Victor ;
Sharma, Padmanee ;
Allison, James ;
Tetzlaff, Michael T. ;
Wargo, Jennifer A. .
NATURE MEDICINE, 2018, 24 (11) :1649-+
[2]  
Antonio S., 2020, COMBINING ATEZOLIZUM, P3
[3]   Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer [J].
Bindea, Gabriela ;
Mlecnik, Bernhard ;
Tosolini, Marie ;
Kirilovsky, Amos ;
Waldner, Maximilian ;
Obenauf, Anna C. ;
Angell, Helen ;
Fredriksen, Tessa ;
Lafontaine, Lucie ;
Berger, Anne ;
Bruneval, Patrick ;
Fridman, Wolf Herman ;
Becker, Christoph ;
Pages, Franck ;
Speicher, Michael R. ;
Trajanoski, Zlatko ;
Galon, Jerome .
IMMUNITY, 2013, 39 (04) :782-795
[4]   Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial [J].
Carthon, Bradley C. ;
Wolchok, Jedd D. ;
Yuan, Jianda ;
Kamat, Ashish ;
Tang, Derek S. Ng ;
Sun, Jingjing ;
Ku, Geoffrey ;
Troncoso, Patricia ;
Logothetis, Christopher J. ;
Allison, James P. ;
Sharma, Padmanee .
CLINICAL CANCER RESEARCH, 2010, 16 (10) :2861-2871
[5]   The role of tumour heterogeneity and clonal cooperativity in metastasis, immune evasion and clinical outcome [J].
Caswell, Deborah R. ;
Swanton, Charles .
BMC MEDICINE, 2017, 15
[6]   Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1 [J].
Champiat, Stephane ;
Dercle, Laurent ;
Ammari, Samy ;
Massard, Christophe ;
Hollebecque, Antoine ;
Postel-Vinay, Sophie ;
Chaput, Nathalie ;
Eggermont, Alexander ;
Marabelle, Aurelien ;
Soria, Jean-Charles ;
Ferte, Charles .
CLINICAL CANCER RESEARCH, 2017, 23 (08) :1920-1928
[7]   Elements of cancer immunity and the cancer-immune set point [J].
Chen, Daniel S. ;
Mellman, Ira .
NATURE, 2017, 541 (7637) :321-330
[8]   Oncology Meets Immunology: The Cancer-Immunity Cycle [J].
Chen, Daniel S. ;
Mellman, Ira .
IMMUNITY, 2013, 39 (01) :1-10
[9]   Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma [J].
Cloughesy, Timothy F. ;
Mochizuki, Aaron Y. ;
Orpilla, Joey R. ;
Hugo, Willy ;
Lee, Alexander H. ;
Davidson, Tom B. ;
Wang, Anthony C. ;
Ellingson, Benjamin M. ;
Rytlewski, Julie A. ;
Sanders, Catherine M. ;
Kawaguchi, Eric S. ;
Du, Lin ;
Li, Gang ;
Yong, William H. ;
Gaffey, Sarah C. ;
Cohen, Adam L. ;
Mellinghoff, Ingo K. ;
Lee, Eudocia Q. ;
Reardon, David A. ;
O'Brien, Barbara J. ;
Butowski, Nicholas A. ;
Nghiemphu, Phioanh L. ;
Clarke, Jennifer L. ;
Arrillaga-Romany, Isabel C. ;
Colman, Howard ;
Kaley, Thomas J. ;
De Groot, John F. ;
Liau, Linda M. ;
Wen, Patrick Y. ;
Prins, Robert M. .
NATURE MEDICINE, 2019, 25 (03) :477-+
[10]   Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis [J].
Cortazar, Patricia ;
Zhang, Lijun ;
Untch, Michael ;
Mehta, Keyur ;
Costantino, Joseph P. ;
Wolmark, Norman ;
Bonnefoi, Herve ;
Cameron, David ;
Gianni, Luca ;
Valagussa, Pinuccia ;
Swain, Sandra M. ;
Prowell, Tatiana ;
Loibl, Sibylle ;
Wickerham, D. Lawrence ;
Bogaerts, Jan ;
Baselga, Jose ;
Perou, Charles ;
Blumenthal, Gideon ;
Blohmer, Jens ;
Mamounas, Eleftherios P. ;
Bergh, Jonas ;
Semiglazov, Vladimir ;
Justice, Robert ;
Eidtmann, Holger ;
Paik, Soonmyung ;
Piccart, Martine ;
Sridhara, Rajeshwari ;
Fasching, Peter A. ;
Slaets, Leen ;
Tang, Shenghui ;
Gerber, Bernd ;
Geyer, Charles E., Jr. ;
Pazdur, Richard ;
Ditsch, Nina ;
Rastogi, Priya ;
Eiermann, Wolfgang ;
von Minckwitz, Gunter .
LANCET, 2014, 384 (9938) :164-172